Needham raises Alnylam price target on bullish Amvuttra outlook

Needham raised its price target on Alnylam Pharmaceuticals (ALNY) to $377 from $320, reiterating a Buy rating, citing increased optimism for the Amvuttra launch in ATTR-CM and revised out-year revenue estimates following a company meeting. This upgrade, alongside recent European Commission approval for Amvuttra in ATTR-CM and positive analyst sentiment from RBC Capital and H.C. Wainwright, underscores confidence in Alnylam's commercial prospects and pipeline. The company also reaffirmed its 2025 product revenue guidance of $2.05-2.25 billion, with analysts anticipating profitability this year, though InvestingPro indicates the stock may be overvalued relative to its fair value.

Analysis

Alnylam Pharmaceuticals (ALNY) is experiencing strong positive sentiment from analysts, highlighted by Needham's price target increase to $377 from $320 while maintaining a Buy rating. This confidence is primarily driven by updated, more optimistic revenue models for its key drug, Amvuttra, following its launch for ATTR-CM, a form of cardiac amyloidosis. The bullish outlook is reinforced by recent European Commission approval for Amvuttra in this indication, based on the HELIOS-B Phase 3 study which demonstrated significant mortality benefits. This view is shared across the street, with RBC Capital maintaining an Outperform rating on positive prescription data and H.C. Wainwright reaffirming a Buy with a $500 price target. Financially, the company reaffirmed its 2025 product revenue guidance of $2.05-2.25 billion, with current revenue growth at 17.21% and analysts anticipating profitability this year. However, despite the strong operational momentum and positive analyst coverage that has propelled the stock up 32.76% in six months to near its 52-week high, an InvestingPro analysis suggests the stock may be overvalued relative to its fair value, introducing a valuation concern for prospective investors.

Key Decisions for Investors

• Investors should recognize the strong commercial and regulatory momentum behind Amvuttra, which, supported by a chorus of positive analyst ratings, presents a clear growth catalyst for the company.
• Given the stock's 32.76% appreciation over the last six months and the signal that it may be overvalued, it is prudent to weigh the compelling growth narrative against the current valuation before initiating or adding to a position.
• Monitor upcoming quarterly reports for Amvuttra's initial sales performance in the ATTR-CM market, as these results will be critical to validating the heightened revenue expectations and supporting the stock's current premium.